Methods Collections

Current developments in nano/micro technologies for translational biomedical applications

COVID-19 response: Video production in affected areas is postponed, publishing text articles first

JoVE will publish text articles after the peer review, which on average takes two months after the manuscript submission. We will film and add corresponding videos to our website when laboratories and facilities in affected areas reopen.

Just Started
Methods Collection Image
Methods Collections
Current developments in nano/micro technologies for translational biomedical applications

Guest Editors
Malathi Mathiyazhakan

National Institute of Epidemiology

Malathi Mathiyazhakan received her B.Tech degree in Industrial Biotechnology from SASTRA University, India. She then...

Collection Overview

Biodegradable nanoparticles and microparticles are extensively researched in the field of biomedical engineering, particularly for (1) controlled-delivery of macromolecules, (2) clinical diagnosis, and (3) drug development.  Owing to their biocompatibility, the majority of these particles are liposomal or polymeric compositions. However, recent advancements in methodologies explore the use of metallic or graphene-based particles as therapeutics and diagnostics. Alongside these, micro-technologies such as microneedles, bio-MEMS, and microfluidics are gaining attention for clinical applications. Although promising at lab-scale, their complete translation into the clinics depends on various parameters that influence the efficiency and efficacy of these nano/micro systems. Nevertheless, with recent advances in the fabrication techniques, immuno-modulatory studies, and imaging modalities, the prospects of bio-medicine are evolving. Localized and controlled drug delivery, precision and personalized medicine, 3D-Printed implants are few concepts on the purview. This method collection aims to compile some of the novel nano/micro technologies which have a strong potential for clinical translation. The collection includes but is not limited to: (1)smart nanomaterials for targeted/controlled drug delivery, (2) graphene-based nanomaterials, (3) metallic nanoparticles, (4) microneedle-based delivery systems, and (5) biomimetic polymers/microfluidic diagnostic platforms.